Title
Hypocretin deficiency associated with narcolepsy type 1 and central hypoventilation syndrome in neurosarcoidosis of the hypothalamus (vol 11, pg 1063, 2015)

Permalink
https://escholarship.org/uc/item/5kf059vv

Journal
JOURNAL OF CLINICAL SLEEP MEDICINE, 12(5)

ISSN
1550-9389

Authors
May, MC
Deng, JC
Albores, J
et al.

Publication Date
2016

Peer reviewed
We report a case of a 53-year-old man presenting with depressed alertness and severe excessive sleepiness in the setting of neurosarcoidosis. Neuroimaging demonstrated hypothalamic destruction due to sarcoidosis with a CSF hypocretin level of 0 pg/mL. The patient also experienced respiratory depression that presumably resulted from hypocretin-mediated hypothalamic dysfunction as a result of extensive diencephalic injury. This is a novel case, demonstrating both hypocretin deficiency syndrome, as well as respiratory dysfunction from destruction of hypocretin neurons and extensive destruction of key diencephalic structures secondary to the underlying neurosarcoidosis.

Keywords: hypocretin, orexin, hypothalamus, neurosarcoid, narcolepsy


Human narcolepsy is currently considered to reflect dysfunction of the hypocretin system. The vast majority of patients with narcolepsy and cataplexy have low or undetectable levels of hypocretin-1 in the cerebrospinal fluid (CSF). Abnormally low hypocretin levels have also been described in cases of secondary narcolepsy due to hypothalamic damage from a variety of CNS causes, including neurosarcoidosis. In this case report, we present a patient with profound hypersomnolence in the setting of neurosarcoidosis of the diencephalon, and respiratory failure secondary to central alveolar hypoventilation.

REPORT OF CASE

A previously healthy 53-year-old man presented with alterations in alertness and hypothalamic lesion noted on MRI. Prior to onset of symptoms, he had unexplained, unintentional weight loss, severe and pathological excessive sleepiness, subjective fevers, and night sweats. Diagnosis of neurosarcoidosis was established by hypothalamic biopsy demonstrating non-caseating granulomas and exclusion of other infectious diseases. No other organ involvement was noted on whole-body positron emission topography (PET) scan, computerized tomography of the chest, or 2D echocardiogram. Chest radiograph was unremarkable with normal lung volumes. The patient underwent treatment for sarcoidosis. Dream enactment, snoring, apneic spells, cataplexy, hallucinatory episodes and sleep paralysis were absent, but sleep fragmentation was present. Physical examination revealed a lethargic, thin man who awakened intermittently to verbal stimuli, but held a very short attention span of approximately 5-to-10 seconds, lapsing back to sleep. During the course of hospitalization, he developed acute hypercapnic respiratory failure of unclear origin.

RESULTS

Laboratory Studies

Lumbar puncture demonstrated a CSF hypocretin level of 0 pg/mL. The CSF was clear and colorless with 2 RBC and 3 WBC, without evidence for demyelination. CSF was negative for the following: coccidiomycosis, cryptococcus, JC virus, toxoplasmosis, VDRL, varicella PCR, HSV1/2 PCR, mycobacterial PCR, acid fast stain and culture, bacterial culture, viral culture, and fungal culture.

HLA DQB1*0602 was negative.

Blood gas showed respiratory acidosis with a pH of 7.29, PaCO₂ = 91 mm Hg, PaO₂ = 50 mm Hg, HCO₃ = 42.6 mmol/L. Subsequent diaphragmatic ultrasound sniff test depicted normal bilateral diaphragmatic movement with respiration. Pulmonary function tests were deferred due to the patient’s diminished mental status. Computerized tomography of the chest before and during his acute respiratory failure depicted only bibasilar atelectasis, stable micronodules without evidence of lesions, or masses along the course of the phrenic nerve. There was no evidence of infiltration of the diaphragm with sarcoid. The patient did not have evidence of lymphadenopathy, pulmonary fibrosis, or disease along the bronchovascular bundle. Phrenic EMGs depicted normal bilateral phrenic nerve compound muscle action potential (CMAPs).
Imaging Studies

Brain magnetic resonance imaging (MRI) indicated involvement of the hypothalamus (Figure 1), with both T2 and T1 post-contrast hyperintensity within that region. No brainstem involvement was detected by MRI at that time, nor were any appreciable lesions found in the locus coeruleus or raphe nuclei.

Sleep Studies

Due to the autonomic and respiratory instability and hypernatremia, the patient was too unstable to be transferred to the sleep center to undergo a formal polysomnogram. Two portable sleep studies were attempted during the course of his hospitalization, but both were technically challenged.

DISCUSSION

The patient’s symptoms appear to represent a central nervous system hypersomnia in the form of narcolepsy type 1 by the International Classification of Sleep Disorders 3, resulting from significant hypothalamic destruction due to neurosarcoidosis. While the majority of patients with narcolepsy type 1 are HLA-DQB1*0602 positive, with its mechanism appearing to be related to decreased numbers of hypocretin secreting cells in the posterolateral hypothalamus, low CSF hypocretin in patients who are negative for the HLA-DQB1*0602 allele, as in this case, are presumed to have a secondary and neurologically-mediated mechanism as a disease phenotype.

We postulate that, in addition to the patient’s severe hypersomnia, his hypoventilation and hypercapnia were also mediated by hypocretin deficiency in the absence of significant pulmonary or neuromuscular pathology to account for this finding. Hypocretin neurons contribute to multiple “drives” of breathing, including thermal drive, forebrain “arousal” influences to the musculature (which includes respiratory muscles), and, of special importance to the findings here, CO₂ facilitation of breathing.

The patient’s prolonged hypoventilation potentially exacerbated neural injury in brainstem respiratory and autonomic areas, leading to impaired ventilation. Studies in another sleep disordered breathing condition, congenital central hypoventilation syndrome (CCHS), show significant injury to hypothalamic, ventral and dorsal medullary, periaqueductal gray, and parabrachial pontine areas. Although medullary and pontine injury did not appear in MRI studies of this case, it is important to note that CCHS MRI studies often do not show injury unless specialized procedures of diffusion tensor imaging or T2 relaxometry studies are collected. Hypocretin plays many excitatory roles, among which is exciting chemoreception. Sensing of chemoreception takes place in many sites in the brain, including areas near the hypothalamus, as well as in projections to medullary and cerebellar chemoreception sites. A loss of hypocretin and its excitatory influence on sensing CO₂ could lead to hypoventilation, and underlie the findings here.

In conclusion, while findings of narcolepsy type 1 are often encountered in patients who present with diencephalic lesions, clinicians who encounter these patients should also pay attention to respiratory function. Hypocretin deficiency is invariably associated with profound hypersomnia, and hypocretin neuronal projections to brainstem structures can mediate a pattern of central hypoventilation syndrome. For this reason, patients presenting with significant diencephalic disease should be monitored carefully, and assessed for development of respiratory failure.

REFERENCES

Hypocretin Deficiency and Narcolepsy in a Case of Hypothalamic Neurosarcoid


ACKNOWLEDGMENTS

The authors thank Dr. Emmanuel Mignot and the Stanford University Center for Narcolepsy and Related Disorders for graciously providing the CSF hypocretin assay.

SUBMISSION & CORRESPONDENCE INFORMATION

Submitted for publication January, 2015
Submitted in final revised form March, 2015
Accepted for publication April, 2015
Address correspondence to: Alon Avidan, MD, MPH, Director, UCLA Sleep Disorders Center, Professor of Neurology, Department of Neurology, David Geffen School of Medicine at UCLA, 710 Westwood Blvd., Room 1-145 RNRC, Los Angeles, CA 90095-1769; Email: avidan@mednet.ucla.edu

DISCLOSURE STATEMENT

This was not an industry supported study. Dr. Avidan has participated in speaking engagements for Merck and UCB and has consulted for Best Doctors. Dr. Zeidler has received research support from and participated in speaking engagements for Forest Pharmaceuticals and has received the loan of research equipment from ResMed. The other authors have indicated no financial conflicts of interest.